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Delayed cerebral ischemia (DCI) is a major contributor to poor outcome after aneurysmal subarachnoid hemor-
rhage (aSAH).1 For 3 decades, induced hypertension, used 
alone or in combination with hemodilution and hypervol-
emia, the so-called triple-H therapy, has been used with the 
aim of restoring impaired cerebral perfusion,2 and thereby 
improving outcome. However, this treatment is not sup-
ported by any controlled study and carries a risk of serious 
complications. In a systematic review of the literature, of the 
components of this triple-H therapy, only induced hyper-
tension seemed useful in actually increasing cerebral blood 
flow.3 The aim of this randomized trial was to assess the 
effectiveness of induced hypertension on clinical outcome in 
patients with DCI after aSAH.
Methods
The data that support the findings of this study are available from the 
corresponding author on reasonable request.
Background and Purpose—Induced hypertension is widely used to treat delayed cerebral ischemia (DCI) after aneurysmal 
subarachnoid hemorrhage, but a literature review shows that its presumed effectiveness is based on uncontrolled case-
series only. We here report clinical outcome of aneurysmal subarachnoid hemorrhage patients with DCI included in a 
randomized trial on the effectiveness of induced hypertension.
Methods—Aneurysmal subarachnoid hemorrhage patients with clinical symptoms of DCI were randomized to induced 
hypertension or no induced hypertension. Risk ratios for poor outcome (modified Rankin Scale score >3) at 3 months, 
with 95% confidence intervals, were calculated and adjusted for age, clinical condition at admission and at time of DCI, 
and amount of blood on initial computed tomographic scan with Poisson regression analysis.
Results—The trial aiming to include 240 patients was ended, based on lack of effect on cerebral perfusion and slow 
recruitment, when 21 patients had been randomized to induced hypertension, and 20 patients to no hypertension. With 
induced hypertension, the adjusted risk ratio for poor outcome was 1.0 (95% confidence interval, 0.6–1.8) and the risk 
ratio for serious adverse events 2.1 (95% confidence interval, 0.9–5.0).
Conclusions—Before this trial, the effectiveness of induced hypertension for DCI in aneurysmal subarachnoid hemorrhage 
patients was unknown because current literature consists only of uncontrolled case series. The results from our premature 
halted trial do not add any evidence to support induced hypertension and show that this treatment can lead to serious 
adverse events.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01613235.   
 (Stroke. 2018;49:76-83. DOI: 10.1161/STROKEAHA.117.017956.)
Key Words: aneurysmal subarachnoid hemorrhage ◼ delayed cerebral ischemia  
◼ induced hypertension ◼ randomized controlled trial
Induced Hypertension for Delayed Cerebral Ischemia 
After Aneurysmal Subarachnoid Hemorrhage
A Randomized Clinical Trial
Celine S. Gathier, MD; Walter M. van den Bergh, MD, PhD; Mathieu van der Jagt, MD, PhD;  
Bon H. Verweij, MD, PhD; Jan Willem Dankbaar, MD, PhD;  
Marcella C. Müller, MD, PhD; Annemarie W. Oldenbeuving, MD, PhD;  
Gabriel J.E. Rinkel, MD, FRCPE; Arjen J.C. Slooter, MD, PhD; for the HIMALAIA Study Group*
Received May 5, 2017; final revision received October 19, 2017; accepted October 23, 2017.
From the Department of Intensive Care Medicine, Brain Center Rudolf Magnus (C.S.G., A.J.C.S.), Department of Neurology and Neurosurgery, Brain 
Center Rudolf Magnus (C.S.G., B.H.V., G.J.E.R.), and Department of Radiology (J.W.D.), University Medical Center Utrecht, Utrecht University, the 
Netherlands; Department of Critical Care, University Medical Center Groningen, University of Groningen, the Netherlands (W.M.v.d.B.); Department 
of Intensive Care and Erasmus MC Stroke Center, Erasmus MC University Medical Center, Rotterdam, the Netherlands (M.v.d.J.); Department of 
Intensive Care, Academic Medical Center Amsterdam, University of Amsterdam, the Netherlands (M.C.M.); and Department of Intensive Care, Elisabeth-
TweeSteden Hospital (ETZ), Tilburg, the Netherlands (A.W.O.).
*A list of all HIMALAIA Study Group participants and their affiliations are given in the Appendix.
Presented in part at the European Stroke Organisation Conference, Prague, the Czech Republic, May 16–18, 2017, and the European Society of Intensive 
Care Medicine Conference, Berlin, Germany, October 3–7, 2015.
Correspondence to Celine S. Gathier, MD, University Medical Center Utrecht, Utrecht University, PO Box 85500, Room F.06.134, 3508 GA, Utrecht, 
the Netherlands. E-mail c.s.gathier-2@umcutrecht.nl
© 2017 American Heart Association, Inc.
Stroke is available at http://stroke.ahajournals.org DOI: 10.1161/STROKEAHA.117.017956
STR
Stroke
0039-2499
10.1161/STROKEAHA.117.017956
STROKE2017017956
Gathier et al  Induced Hypertension for DCI After Aneurysmal SAH
1
January
2018
49
1
76
83
5May201719October201723October2017
© 2017 American Heart Association, Inc.
2017
10155,10162,10173
Reshma R
Stroke
Clinical
D
ow
nloaded from
 http://ahajournals.org by on January 15, 2019
Gathier et al  Induced Hypertension for DCI After Aneurysmal SAH  77
Study Design and Patients
From 2009 to 2015, we performed a multicenter, single-blinded, ran-
domized trial with masked outcome assessment in 4 hospitals in the 
Netherlands to assess the effects of induced hypertension on cerebral 
perfusion and clinical outcome in aSAH patients with DCI. The study 
was approved by the medical ethics committee (protocol number 
METC 2010_157) and all participating hospitals.
The trial design including in- and exclusion criteria for participation 
was published previously.4 In short, informed consent was obtained as 
soon as possible after admission. In case of a depressed level of con-
sciousness, the patient’s legal representative was asked for informed con-
sent. Eligible patients in whom informed consent was obtained and in 
whom the symptomatic aneurysm was occluded were randomized at the 
time of development of DCI, defined as a decrease of at least 1 point on 
the Glasgow Coma Scale sum score or development of new focal neuro-
logical deficits lasting at least 1 hour, or both, with exclusion of other pre-
specified explanations for clinical deterioration. To exclude these other 
options, we routinely performed a computed tomographic (CT) scan of 
the brain to rule out hydrocephalus and sampled blood to determine leu-
cocytes count and serum CRP (C-reactive protein), sodium, creatinine, 
urea, and glucose to exclude a metabolic encephalopathy. In case of any 
suspicion, an electroencephalogram was performed to rule out seizures.
We further excluded patients with a spontaneous mean arterial 
pressure (MAP) >120 mm Hg at time of randomization and patients 
with contraindications for induced hypertension according to the 
treating physician. Randomization was initially performed using 
sealed opaque envelopes but later changed to Web-based randomiza-
tion with stratification for treatment center with maximum random 
block size of 8.4
Interventions
Patients were randomized to induced hypertension or no hypertension 
(no hypertension group). Hypertension needed to be started within 3 
hours after the start of clinical symptoms of DCI. Hypertension was 
induced with fluids and norepinephrine over a central venous line 
placed for this purpose in the intensive care unit (ICU) according to the 
local protocol of the participating center. The treatment was continued 
until improvement of neurological deficits, occurrence of a complica-
tion, a maximum MAP of 130 mm Hg, or a systolic blood pressure of 
230 mm Hg. Clinical improvement within 24 hours was judged by the 
unblinded treating clinician. In case of clinical improvement, norepi-
nephrine was continued for at least 48 hours and then slowly tapered. 
In case of recurrence of symptoms during tapering, norepinephrine 
was restarted and tapering was attempted 24 hours later. In the absence 
of clinical improvement within 24 hours, norepinephrine was tapered. 
In the no hypertension group, hypertension was not induced, but a 
minimal MAP of 80 mm Hg was maintained with fluids and, when 
necessary, with vasopressors. In the latter case, a central venous line 
was placed, but otherwise, no central venous lines were used in the no 
hypertension group. Patients in the hypertension group were managed 
at the ICU and patients in the no hypertension group could be man-
aged either at a neuro-medium care unit or ICU depending on blood 
pressure and level of consciousness. In case of a second episode of 
DCI, treatment was performed according to the initial randomization. 
Hourly, nurse-validated invasive measures of MAP were obtained for 
analyses. In patients in the no hypertension group who remained at the 
neuro-medium care unit, MAP was obtained noninvasively at least 4 
hourly. All patients were treated with oral nimodipine and fluid admin-
istration aimed at normovolemia. In 3 of the 4 participating centers, a 
substudy was performed to assess the efficacy of induced hypertension 
in augmenting cerebral blood flow by means of cerebral perfusion CT 
scanning.5 In these patients, follow-up CT perfusion was obtained 24 
to 36 hours after randomization. In the fourth center, follow-up CT or 
magnetic resonance imaging was not routinely performed.
Outcome Measures
Outcome measures were obtained by research nurses blinded for treat-
ment allocation. The primary outcome measure was poor outcome at 
3 months (modified Rankin Scale >3).6 Secondary outcome measures 
were cerebral perfusion assessed with CT perfusion (data published 
previously5), 30-day case-fatality, and, at 3 months after randomiza-
tion: activities of daily living (Barthel Index7), quality of life (Stroke 
Specific Quality of Life Scale8), anxiety and depression (Hospital 
Anxiety and Depression Scale9), and cognitive functioning (Cognitive 
Failures Questionaire10). All serious adverse events (SAE’s) were 
recorded during hospital admission by the principle investigator.4 
For the current study, an SAE was defined according to the defini-
tion made by the Central Committee on Research Involving Human 
Subjects (the Centrale Commissie Mensgebonden Onderzoek) at the 
time of drafting the study protocol, following the definition made by 
the European Commission. The Centrale Commissie Mensgebonden 
Onderzoek defines an SAE as follows: an SAE is any untoward medi-
cal occurrence in a patient or trial subject, which does not have a 
causal relationship with the treatment, and: (1) results in death; (2) is 
life threatening (at the time of the event); (3) requires prolongation of 
inpatients’ hospitalization; (4) results in persistent or significant dis-
ability or incapacity; (5) is a new event of the trial likely to affect the 
safety of the subjects.11–13 For the present study, SAEs were defined 
according to the definition above, within the timeframe of hospital 
admission. In case of death, the cause of death was determined by the 
principle investigator of each participating center. In case the cause of 
death was not immediately clear, the entire period of hospital admis-
sion was reviewed to establish the factors contributing to death.
Statistical Analysis
With an expected frequency of poor outcome of 42%, power of 80%, 
and significance level set at 0.05, we calculated that a sample of 120 
patients per group would be needed to detect a relative risk of 0.60 for 
poor outcome associated with induced hypertension. MAP over time 
was compared between groups with a linear mixed model. We calcu-
lated risk ratio’s with corresponding 95% confidence intervals (CI) 
for poor outcome and for occurrence of SAEs. In addition, we com-
puted adjusted risk ratios for poor outcome, adjusted for age, clini-
cal condition at admission, and at time of DCI based on the World 
Federation of Neurosurgical Societies scale14 and amount of blood 
on initial CT scan using the Hijdra-score, with Poisson regression 
analysis. We primarily performed an intention-to-treat analysis and 
added an on-treatment sensitivity analysis. For the remaining second-
ary outcome measures, differences between groups were assessed 
with Mann–Whitney U tests.
Trial Organization
An independent data safety monitoring board (DSMB) was appointed 
for this study and consisted of a biostatistician, a neurologist-inten-
sivist, and an internist-intensivist, none of whom were involved in 
the trial otherwise. The responsibility of the DSMB was to assess 
safety, continued scientific value, overall conduct of the trial, treat-
ment harm and recruitment, with the aim of providing recommenda-
tions on (dis)continuation of the trial. Reports to the DSMB were 
provided by the study coordinator every 3 months or after every 5 ran-
domized patients. The DSMB met at least every 6 months. A formal 
interim analysis was planned after 120 patients completed the trial. In 
2014, an additional interim analysis was advised by the DSMB when 
recruitment was slow, after 24 patients completed the substudy on 
cerebral perfusion. The aim of this interim analysis was to calculate 
how much patients would be needed to find a statistically significant 
difference in cerebral perfusion and assess feasibility of continuation 
of the trial based on safety data of all included patients at that time.
Results
The trial was prematurely terminated based on advice of 
the Data Safety Monitoring Board because of lack of effect 
on overall cerebral perfusion5 and slow recruitment result-
ing in the conclusion that it would be unfeasible to obtain 
sufficient numbers of included subjects within a reasonable 
time frame. At the time of termination of the trial, in total 
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an estimated 1627 patients had been screened for participa-
tion of whom 736 were eligible. In one of the participating 
centers, enrolling 5 patients in total, the documentation of 
the exact number of patients screened for participation was 
not structurally assessed at the beginning of the trial. This 
center stopped including patients after 2 years. Of all eli-
gible patients (n=736), 248 gave informed consent, and of 
these, 41 developed DCI and could be randomized: 21 to 
induced hypertension and 20 to the no hypertension group 
(Table 1). In 1 patient, randomized to the hypertension 
group, treatment was not started because of the discovery of 
a previously unknown cardiomyopathy. Twenty-five of the 
41 randomized patients also participated in the substudy on 
cerebral perfusion.5
The MAP over the first 24 hours was 11.1 mm Hg (95% CI, 
7.1–15.1) higher in the hypertension group than in no hyper-
tension group. The difference in MAP between the hyperten-
sion group and the no hypertension group over 72 hours was, 
on average, 5.7 mm Hg (95% CI, 4.2–8.5 mm Hg; Figure). In 
5 of the 20 patients in the no hypertension group, norepineph-
rine was administered over a central venous line for several 
hours to prevent a MAP <80 mm Hg.
Poor outcome occurred in 12 of 21 (57%) patients in the 
hypertension group and in 8 of 20 (40%) patients in the no 
hypertension group. With induced hypertension, the risk ratio 
for poor outcome was 1.4 (95% CI, 0.7–2.7) and the adjusted 
risk ratio 1.0 (95% CI, 0.6–1.8). In the on-treatment analy-
ses, the adjusted risk ratio for poor outcome associated with 
induced hypertension was 1.1 (95% CI, 0.6–1.9).
Eighteen patients showed clinical improvement within 24 
hours (n=12, 57% in the hypertension group and n=6, 30% 
in the no hypertension group), defined as any improvement 
in Glasgow coma score or improvement of focal deficits, 
according to the treating clinician. Five of the 12 patients 
with initial improvement after induced hypertension had a 
poor outcome at 3 months, whereas 0 of the 6 patients with 
initial improvement without induced hypertension had a poor 
outcome at 3 months.
Secondary outcome measures are shown in Table 1. Sixteen 
SAE’s occurred, 11 (52%) in the hypertension group versus 5 
(25%) in the no hypertension group, risk ratio 2.1 (95% CI, 
0.9–5.0).
Specification of the SAE’s in the hypertension group ver-
sus the no hypertension group was as follows: death 6/4, 
pneumothorax 2/0, atrial fibrillation 1/0, myocardial infarc-
tion 2/0, ECG changes (diffuse negative ECG T-waves): 0/1. 
Specification of the deaths was as follows: 6 patients died in 
the hypertension group because of persistent poor neurologi-
cal condition due to the aSAH and DCI (n=2), pneumosepsis 
superimposed on poor neurological condition (n=1), rebleed-
ing from previously coiled symptomatic aneurysm, weeks 
after discharge (n=1), combination of poor neurological con-
dition, acute coronary syndrome, pneumosepsis, and meta-
bolic disturbances (n=1), and unexpected death of unknown 
cause 1 day before discharge from the hospital (n=1). Four 
patients died in the no hypertension group because of persis-
tent poor neurological condition due to the aSAH and DCI 
(n=3) and pneumonia superimposed on poor neurologi-
cal condition (n=1). In 1 patient in the hypertension group, 
Table 1. Patient Characteristics and Outcome Measures per 
Group
 
Induced 
Hypertension 
(n=21)
No 
Hypertension 
(n=20) RR (95% CI)
Patient characteristics
  Age, mean (SD) 63 (12) 57 (10)  
  Female (%) 15 (71) 16 (80)  
  Medical history of 
hypertension (%)
5 (24) 4 (20)  
  Admission-WFNS-score 
>3
12 (57) 8 (40)  
  WFNS-score at DCI >3 13 (62) 11 (55)  
  Anterior circulation 
aneurysm (%)
16 (76) 13 (65)  
  Hijdra sum score 
>median of 28 (%)
13 (62) 7 (35)  
  Clip/coil (%) 9(43)/12(57) 8(40)/12(60)  
  Rebleeding (%) 1 (5) 2 (10)  
  Days between aSAH and 
DCI, median (IQR)
6 (4–7) 8 (5–9.8)  
  Time DCI to start of 
hypertension (h), median 
(IQR)
3.4 (3–5.4) –  
  Baseline MAP, mean (SD) 99 (13) 99 (11)  
Outcome measures
  Poor outcome at 3 mo, 
mRS >3 (%)
12 (57) 8 (40) 1.0* (0.6–1.8)
  mRS (%) 0 0 2 (11)  
   1 1 (5) 4 (21)  
   2 6 (29) 3 (16)  
   3 2 (10) 3 (16)  
   4 3 (14) 3 (16)  
   5 3 (14) 1 (5)  
   6 6 (29) 4 (21)  
  SAE’s 11 (52) 5 (25) 2.1 (0.9–5.0)
  ADL (Barthel Index7; 
median, IQR)†
20 (10–20) 20 (16–20)  
  Quality of life (SSQoL8; 
median, IQR)†
47 (35–55) 49 (35–55)  
  Anxiety and depression 
(HADS9; median, IQR)†
13 (3–13) 8 (4–11)  
  Cognitive functioning 
(CFQ10; median, IQR)†
29 (16–54) 26 (15–33)  
ADL indicates activities of daily living; aSAH, aneurysmal subarachnoid 
hemorrhage; CFQ, Cognitive Failures Questionnaire; CI, confidence interval; CT, 
computed tomography; DCI, delayed cerebral ischemia; HADS, Hospital Anxiety 
and Depression Scale; IQR, interquartile range; MAP, mean arterial pressure; 
mRS, modified Rankin Scale at 3 months; RR, risk ratio; SSQoL, Stroke Specific 
Quality of Life Scale; and WFNS, World Federation of Neurosurgical Societies.
*Adjusted for age, clinical condition at admission, clinical condition at time of 
DCI, and amount of blood on initial CT scan.
†Assessed in 9 patients in the hypertension group and 11 patients in the no 
hypertension group.
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more than 1 SAE occurred. This patient developed 3 SAEs: 
a pneumothorax because of insertion of the central venous 
line necessary for the administration of norepinephrine, an 
acute coronary syndrome after initiation of induced hyperten-
sion for which induced hypertension was tapered, and death 
because of a combination of poor neurological condition, the 
acute coronary syndrome, pneumosepsis, and metabolic dis-
turbances. All these events were judged as individual SAEs 
following the predefined definition for a SAE.
Discussion
In this randomized trial, induced hypertension effectively 
increased blood pressure. Because the study was stopped pre-
maturely because of lack of efficacy on cerebral blood flow 
and slow recruitment, it remains underpowered and therefore 
does not provide any evidence to support induced hyperten-
sion in aSAH patients with DCI. Our study also shows that 
induced hypertension can lead to serious adverse events. The 
unblinded treating physicians had the impression that induced 
hypertension improved the symptoms associated with clini-
cal DCI, but the trial showed that clinical improvement also 
occurs in the absence of induced hypertension.
To put our data in perspective with the current available 
literature, we performed an extensive literature search in the 
Entrez PubMed NIH and EMBASE online medical databases, 
and the central COCHRANE Controlled Trial Register (last 
search date August 31, 2017), using the search string outlined 
in Table 2. Reference lists were checked for completeness. We 
included only original reports, based on adult human subjects 
with proven aSAH. At least part of the study population had 
to be treated with induced hypertension with vasopressors as 
treatment for clinical signs of DCI. Only studies that reported 
on clinical response to the treatment or effects on functional 
outcome were included; those reporting on angiographic or 
other imaging studies were excluded. Case reports, reviews, 
and articles that were not obtainable in full-text or in English 
were also excluded.
The search yielded 1294 results, of which only 14 met the 
selection criteria (Table 3).15–28 No additional studies were 
identified checking the reference lists. Of the 14 studies (total-
ling 490 patients), 9 (with 324 patients) had a prospective 
design, but none had a control or comparison group. Numbers 
of included patients ranged from 4 to 95. The definition of 
DCI differed between studies with some studies also including 
patients without clinical signs of DCI. The intervention also 
differed substantially between studies, with some studies also 
using prophylactic or therapeutic hypervolemia besides thera-
peutic induced hypertension. Furthermore, in several studies, 
nonresponders to induced hypertension were additionally 
treated with positive inotropic medication, balloon angio-
plasty, or vasodilators, such as papaverine and milrinone. In 
the 14 studies, information on clinical response to the inter-
vention was provided in 9 (187 patients), information on long-
term functional outcome in 5 (141 patients), and information 
on complications because of the intervention in 7 studies (285 
patients).
In the 9 studies with 187 patients reporting on clinical 
response to the intervention, improvement of neurologi-
cal deficits ranged from 50% to 100%, with most studies 
reporting improvement in around 80% of patients. In the 
Figure. Mean arterial pressure (MAP) over time per group.
Table 2. Search String
((((((((subarachnoid haemorrhage[Title/Abstract]) OR subarachnoid hemorrhage[Title/Abstract]) OR intracranial arterial aneurysms[Title/Abstract]) OR intracranial 
aneurysms[Title/Abstract]) OR intracranial aneurysm[Title/Abstract]) OR intracranial arterial aneurysm[Title/Abstract]))
AND (((((((((((((((((((((delayed cerebral ischemia[Title/Abstract]) OR delayed cerebral ischaemia[Title/Abstract]) OR delayed ischemia[Title/Abstract]) OR delayed 
ischaemia[Title/Abstract]) OR ischemic deficits[Title/Abstract]) OR ischemic deficit[Title/Abstract]) OR ischaemic deficits[Title/Abstract]) OR ischaemic deficit[Title/
Abstract]) OR delayed ischemic neurological deficit[Title/Abstract]) OR delayed ischaemic neurological deficit[Title/Abstract]) OR delayed ischemic neurological 
deficits[Title/Abstract]) OR delayed ischaemic neurological deficits[Title/Abstract]) OR vasospasm[Title/Abstract]) OR symptomatic vasospasm[Title/Abstract]) 
OR cerebral perfusion[Title/Abstract]) OR delayed neurological deterioration[Title/Abstract]) OR cerebral blood flow[Title/Abstract]) OR cerebral vasospasm[Title/
Abstract]) OR delayed cerebral vasospasm[Title/Abstract]) OR delayed ischemic neurological deterioration[Title/Abstract]) OR delayed ischaemic neurological 
deterioration[Title/Abstract]))
AND (((((((((((((((((((induced hypertension[Title/Abstract]) OR hypertension[Title/Abstract]) OR triple-H[Title/Abstract]) OR triple-H therapy[Title/Abstract]) OR triple H 
therapy[Title/Abstract]) OR triple H[Title/Abstract]) OR induced arterial hypertension[Title/Abstract]) OR arterial hypertension[Title/Abstract]) OR blood pressure[Title/
Abstract]) OR blood pressure augmentation[Title/Abstract]) OR volume expansion therapy[Title/Abstract]) OR hyperdynamic[Title/Abstract]) OR vasopressor[Title/
Abstract]) OR vasopressors[Title/Abstract]) OR hypervolemic[Title/Abstract]) OR hemodynamic augmentation[Title/Abstract]) OR haemodynamic augmentation[Title/
Abstract]) OR vasopressor-induced hypertension[Title/Abstract]) OR hypervolaemic[Title/Abstract])
For EMBASE and Cochrane: [Title/Abstract] was replaced by:ti,ab.
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Table 3. Characteristics of Included Studies
Reference Prospective Nr. Int/No Int.
Control 
Group DCI Definition Intervention
Clinical 
Response
Functional 
Outcome Complications
Roy et al26
− 63/0 −
Clinical 
deterioration not 
attributable to other 
causes.
iHT with PE or NE.
Nonresponders 
(n=34) were 
additionally treated 
with endovascular 
therapy.
49 (82%).
Good outcome 3 
mo: 31 (49%).
Cardiac arrhythmia: 
31 (49%) ECG 
changes: 29 (46%); 
troponin elevation: 
9 (14%); pulmonary 
edema: 15 (24%).
Death during 
admission: n.a.
Murphy et 
al22
−
13/0*
(2 patients 
received iHT 
prophylactically).
−
Clinical 
deterioration not 
attributable to other 
causes.
iHT with NE.
One patient was 
additionally treated 
with intra-arterial 
milrinone.
n.a.
Good outcome 3 
mo: 6 (46%)
n.a.
Death during 
admission: n.a.
Frontera 
et al17
+
95, of whom 81 
received iHT/0
−
Clinical 
deterioration not 
attributable to 
other causes, 
with associated 
vasospasm on DSA.
Hypervolemia 
followed by iHT with 
PE or NE.
Nonreceived 
inotropes and 
blood transfusions 
(number not 
provided).
Twenty-seven 
patients underwent 
balloon angioplasty.
Unclear, as 
this was only 
assessed for 
patients with 
poor outcome.
Good outcome 3 
mo: 49 (52%).
n.a.
Death during 
admission: 26%
Raabe et 
al25
+ 45/0 −
Clinical deterioration 
not attributable 
to other causes 
or impending 
cerebral ischemia 
as indicated by 
tissue oxygenation, 
SSEPs, or TCD 
ultrasonography 
findings, with 
associated 
vasospasm on DSA.
Stepwise protocol: 
moderate iHT with 
NE or dopamine, 
followed by either 
increased iHT 
or addition of 
hypervolemia.
n.a.
Good outcome 6 
mo: 17 (38%).
Hyponatremia: 
1 (2%); cardiac 
arrhythmia: 2 (4%); 
pulmonary edema: 3 
(7%); brain edema: 
2 (4%). Death during 
admission n.a.
Aiyagari et 
al15
− 12/0 −
Clinical 
deterioration not 
attributable to other 
causes.
Fluids, PE, 
dopamine, or 
dobutamine.
6 (50%). n.a.
Cardiac arrhythmia: 2 
(17%). Death during 
admission: n.a.
Qureshi et 
al24
− 70/0 −
Clinical 
deterioration not 
attributable to 
other causes, 
with associated 
vasospasm on 
DSA or TCD 
ultrasonography.
Hypervolemia 
(n=70) and iHT 
(n=67) using 
intravenous 
vasopressors.
Twenty-four 
patients also 
received papaverine 
or angioplasty.
n.a.
Good outcome 2 
mo: 38 (54%).
n.a.
Death during 
admission: 20%
Miller et 
al20
+ 24/0 −
Clinical 
deterioration not 
attributable to other 
causes.
Hypervolemia and 
iHT with PE and 
in 4 patients also 
dopamine and 
dobutamine.
Eight patients 
also received 
papaverine.
21 (88%). n.a.
CK-MB elevation: 
1 (4%); T-wave 
inversion: 1 
(4%); increasing 
bradycardia: 1 (4%); 
pulmonary edema of 
whom 4 symptomatic: 
9 (38%). Death during 
admission: 0%
(Continued )
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5 studies with 141 patients reporting on long-term func-
tional outcome, a good functional outcome at 2 to 6 months 
was seen in 38% to 54% of patients. The reported com-
plications from 7 studies (285 patients) are all shown in 
Table 3. Serious complications, such as cardiac arrhythmia, 
pulmonary edema, hemorrhagic transformation, and intra-
cranial bleeding occurred in 2% to 49%, with death occur-
ring in 0% to 26%.
These numbers are comparable to our rates of improvement 
and complications during induced hypertension. The early 
Swift and 
Solomon27
− 8/0 −
Clinical 
deterioration 
with exclusion 
of postoperative 
hemorrhage or 
hydrocephalus.
Reinstitution of 
hypervolemia and 
iHT with dopamine 
or PE.
Not clear, data 
not provided for 
all 8 patients.
n.a.
n.a.
Death during 
admission: 25%
Touho et 
al28
+ 8/0 −
Clinical 
deterioration and 
proven vasospasm 
on angiography.
iHT with dopamine. 7 (88%). n.a.
n.a.
Death during 
admission: 0%
Otsubo et 
al23
+ 41/0 −
Clinical 
deterioration 
with associated 
vasospasm on 
DSA or TCD 
ultrasonography.
iHT with dopamine 
and dobutamine.
22 (54%). n.a.
Hemorrhagic 
infarction: 4 
(10%); intracranial 
hematoma: 3 (7%); 
rebleeding from 
previously clipped 
aneurysm: 1 (2%); 
coagulopathy: 3 (7%); 
cardiac arrhythmia: 
3 (7%); pulmonary 
edema: 1 (2%). Death 
during admission: 0%
Awad et 
al16
+ 42/0 −
Clinical 
deterioration not
 attributable to 
other causes than 
DCI.
Hypervolemia, 
hemodilution, 
and iHT with 
dopamine or other 
vasopressors. iHT 
was only instituted 
in 16 patients.
25 (60%). n.a.
Pulmonary edema: 
3 (7%); rebleeding 
from untreated 
symptomatic 
aneurysm: 1 (2%).
 Death during 
admission: 17%
Muizelaar 
and 
Becker 21
+ 4/0 −
Clinical 
deterioration.
iHT with PE. 4 (100%). n.a.
n.a.
Death during 
admission: 0%
Kassel et 
al18
+ 58/0 −
Clinical 
deterioration, 
with associated 
vasospasm on DSA.
Hypervolemia and 
iHT with dopamine, 
dobutamine, NE, 
metaraminol, 
isoprotenerol, and 
vasopressors.
47 (81%). n.a.
Pulmonary edema: 
10, of whom 2 
symptomatic: (17%); 
hyponatremia: 2 
(3%); rebleeding 
from untreated 
symptomatic 
aneurysm: 3 (5%); 
coagulopathy: 2 (3%); 
hemathorax: 1 (2%); 
myocardial infarction: 
1 (2%).
Death during 
admission: 3%
Kosnik 
and Hunt19 + 7/0 −
Clinical 
deterioration.
iHT with NE. 6 (86%). n.a.
n.a.
Death during 
admission: 14%
DCI indicates delayed cerebral ischemia; DSA, digital substraction angiography; iHT, induced hypertension; Int, intervention; n.a., not assessed; NE, norepinephrine; 
Nr., number of patients; PE, phenylephrine; SSEP, somato sensory evoked potential; and TCD, transcranial Doppler ultrasonography.
*Twelve patients received no iHT and were used as a control group. However, because these patients had no DCI, they could not serve as a control group for assessing 
effectiveness of therapeutically induced hypertension.
Table 3. Characteristics of Included Studies
Reference Prospective Nr. Int/No Int.
Control 
Group DCI Definition Intervention
Clinical 
Response
Functional 
Outcome Complications
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clinical improvement after induced hypertension in these case 
series may explain why induced hypertension has been per-
ceived and recommended as an effective treatment. However, 
as we found in our trial, early clinical improvement after 
induced hypertension does not always confer to a good out-
come, and early clinical improvement occurs without induced 
hypertension.
Our study has limitations that need to be addressed. The 
most important limitation is the limited power because of the 
smaller study population size than planned. We can, therefore, 
not exclude a potential overall benefit of induced hyperten-
sion. Another limitation is the large number of patients who 
were excluded from the trial either because of ineligibility or 
because of declined informed consent. Strength of the study is 
the randomized controlled design allowing more firm conclu-
sions on the effect of induced hypertension than in previous 
studies.
A possible benefit of induced hypertension on DCI could be 
limited to a certain subgroup of patients with aSAH. It is, how-
ever, unclear what the characteristics of this subgroup would 
be. Similarly, some subsets of patients may be more prone to 
complications from induced hypertension. From our study, we 
could not identify such a subgroup. Patients with preexisting 
cardiopulmonary disease are likely to be at increased risk of 
developing more serious complications from induced hyper-
tension, but as a past medical history of cardiopulmonary dis-
ease was an exclusion criterion for our trial, we have no data 
to substantiate this.
Other possible explanations for not finding a difference in 
efficacy are insufficient increase in blood pressure, too late 
initiation, or too short duration of the treatment. Furthermore, 
the difference in management location between the treatment 
groups (ICU versus ICU or neuro-medium care unit) might 
have influenced outcome. In addition, as the clinical diagnosis 
of DCI can be difficult, we might have included patients whose 
clinical deterioration was not caused by DCI even though 
we thoroughly tried to exclude other causes. Alternatively, 
an explanation is that indeed induced hypertension is not 
effective because other factors than vasospasm alone play an 
important role in the development of DCI, such as cortical 
spreading ischemia and microvasculature disturbances.29 This 
explanation is supported by our previously published lack of 
efficacy of induced hypertension to improve overall cerebral 
perfusion.5
Ideally, given the uncertainty on efficacy on clinical out-
come and the risk of complications in our trial, a larger 
randomized trial to evaluate the effectiveness of induced 
hypertension should be undertaken. However, since enrol-
ment has been proven difficult, such a trial would require a 
large number of participating centers and thus would probably 
imply a large international effort. Alternatively, when further 
research can establish which patients have a high potential for 
effect and low risk of complications of induced hypertension, 
a trial on this subgroup of patients may be more feasible with 
less subjects.
In conclusion, induced hypertension is a labor-intensive 
treatment that requires patients to be admitted to an ICU with 
intensive monitoring. Despite its widespread application, 
there is still no evidence that induced hypertension improves 
outcome in patients with DCI, whereas all studies, including 
our own, show a high rate of serious complications associated 
with induced hypertension. Considering the results of the cur-
rent trial, the absence of any other comparative studies and 
the lack of effect on cerebral perfusion, the widespread use of 
induced hypertension in aSAH patients with DCI and the perti-
nent guideline recommendations may require reconsideration.
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Fop van Kooten, Aad van der Lugt (8 patients); Academic Medical 
Center Amsterdam, the Netherlands: Walter M. van den Bergh (cur-
rently: University Medical Center Groningen, the Netherlands), Bert 
A. Coert, Janneke Horn, Marcella C. Müller, W. Peter Vandertop 
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Netherlands: Gus N. Beute, Annemarie W. Oldenbeuving, Bram van 
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patients).
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